CN1738834A - Hcv 疫苗 - Google Patents

Hcv 疫苗 Download PDF

Info

Publication number
CN1738834A
CN1738834A CNA2003801088698A CN200380108869A CN1738834A CN 1738834 A CN1738834 A CN 1738834A CN A2003801088698 A CNA2003801088698 A CN A2003801088698A CN 200380108869 A CN200380108869 A CN 200380108869A CN 1738834 A CN1738834 A CN 1738834A
Authority
CN
China
Prior art keywords
hcv
core
protein
vaccine
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801088698A
Other languages
English (en)
Chinese (zh)
Inventor
S·布雷特
P·A·汉布林
L·奥吉尔维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1738834A publication Critical patent/CN1738834A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2003801088698A 2002-11-15 2003-11-13 Hcv 疫苗 Pending CN1738834A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0226722.7 2002-11-15
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine

Publications (1)

Publication Number Publication Date
CN1738834A true CN1738834A (zh) 2006-02-22

Family

ID=9947928

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2003801088698A Pending CN1738834A (zh) 2002-11-15 2003-11-13 Hcv 疫苗
CNA200380108865XA Pending CN1738833A (zh) 2002-11-15 2003-11-13 Hcv疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA200380108865XA Pending CN1738833A (zh) 2002-11-15 2003-11-13 Hcv疫苗

Country Status (21)

Country Link
US (4) US20060246090A1 (enExample)
EP (2) EP1560845A1 (enExample)
JP (2) JP2006518331A (enExample)
KR (2) KR20050085010A (enExample)
CN (2) CN1738834A (enExample)
AR (1) AR041964A1 (enExample)
AU (2) AU2003288084A1 (enExample)
BR (2) BR0316244A (enExample)
CA (2) CA2504654A1 (enExample)
CO (1) CO5700833A2 (enExample)
GB (1) GB0226722D0 (enExample)
IS (2) IS7830A (enExample)
MA (2) MA27699A1 (enExample)
MX (2) MXPA05005203A (enExample)
NO (2) NO20052136L (enExample)
NZ (2) NZ539999A (enExample)
PL (2) PL376967A1 (enExample)
RU (2) RU2363492C2 (enExample)
TW (1) TW200502246A (enExample)
WO (2) WO2004046175A1 (enExample)
ZA (2) ZA200503803B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102233137A (zh) * 2010-04-30 2011-11-09 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
CN101400366B (zh) * 2006-03-09 2012-12-12 特兰斯吉恩股份有限公司 丙型肝炎病毒非结构性融合蛋白
CN119504957A (zh) * 2025-01-16 2025-02-25 中山大学 一种佐剂及其在制备疫苗中的应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
KR20070068460A (ko) * 2004-10-18 2007-06-29 글로브이뮨 만성 ｃ형 간염에 대한 효모계 치료
JP5405832B2 (ja) * 2006-01-04 2014-02-05 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｈｃｖ特異的なｔ細胞の活性化
EP2044198A4 (en) 2006-07-27 2010-09-08 Ligocyte Pharmaceuticals Inc CHIMERIC INFLUENZA VIRUS TYPE PARTICLES
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
RU2370776C2 (ru) * 2007-11-08 2009-10-20 Общество с ограниченной ответственностью "Диагностические Центры "Алкор Био" Набор антигенов для раздельного выявления антител к структурным и неструктурным белкам вируса гепатита с
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
CA2722423A1 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
KR20110045010A (ko) * 2008-07-24 2011-05-03 아두로 바이오테크 Ｃ형 간염의 치료를 위한 조성물 및 방법
EP2331125A4 (en) 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
US8920812B2 (en) 2009-11-03 2014-12-30 Takeda Vaccines, Inc. Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
RU2019107976A (ru) 2013-02-21 2019-08-23 Тёрнстоун Лимитед Партнершип Композиция вакцины

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
WO1989004669A1 (en) * 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
CA2070952A1 (en) * 1991-06-11 1992-12-12 Makoto Seki Gene of hepatitis c virus or fragment thereof, polypeptide encoded by the same
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
NZ296304A (en) * 1994-10-05 1999-06-29 Apollon Hepatitis c vaccine components
AU5924396A (en) * 1995-05-22 1996-12-11 Bionova Corporation Compositions and methods for the diagnosis of, and vaccinati on against, hepatitis c virus (hcv)
CA2257137A1 (en) * 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
AU774887B2 (en) * 1999-07-09 2004-07-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
ES2411096T3 (es) * 1999-10-27 2013-07-04 Novartis Vaccines And Diagnostics, Inc. Activación de linfocitos T específicos contra el VHC
DE60036881T2 (de) * 1999-11-24 2008-07-10 Novartis Vaccines and Diagnostics, Inc., Emeryville Neues nichtstrukturelles hcv-polypeptid
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400366B (zh) * 2006-03-09 2012-12-12 特兰斯吉恩股份有限公司 丙型肝炎病毒非结构性融合蛋白
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
CN102233137A (zh) * 2010-04-30 2011-11-09 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
CN119504957A (zh) * 2025-01-16 2025-02-25 中山大学 一种佐剂及其在制备疫苗中的应用

Also Published As

Publication number Publication date
US20090104231A1 (en) 2009-04-23
WO2004046175A1 (en) 2004-06-03
RU2005113691A (ru) 2006-01-27
PL376882A1 (pl) 2006-01-09
TW200502246A (en) 2005-01-16
MXPA05005202A (es) 2006-01-27
NZ539998A (en) 2008-04-30
JP2006518331A (ja) 2006-08-10
CN1738833A (zh) 2006-02-22
ZA200503802B (en) 2006-08-30
NO20052136D0 (no) 2005-05-02
US20060246090A1 (en) 2006-11-02
NO20052149D0 (no) 2005-05-02
NO20052136L (no) 2005-07-11
WO2004046176A1 (en) 2004-06-03
BR0316291A (pt) 2005-10-11
KR20050085010A (ko) 2005-08-29
IS7830A (is) 2005-04-28
MXPA05005203A (es) 2006-01-27
CA2504654A1 (en) 2004-06-03
EP1560844A1 (en) 2005-08-10
MA27700A1 (fr) 2006-01-02
MA27699A1 (fr) 2006-01-02
KR20050085009A (ko) 2005-08-29
NO20052149L (no) 2005-07-11
PL376967A1 (pl) 2006-01-23
CO5700833A2 (es) 2006-11-30
NZ539999A (en) 2008-03-28
US20090232847A1 (en) 2009-09-17
GB0226722D0 (en) 2002-12-24
AR041964A1 (es) 2005-06-01
AU2003288084A1 (en) 2004-06-15
IS7831A (is) 2005-04-28
ZA200503803B (en) 2006-08-30
BR0316244A (pt) 2005-10-04
AU2003288072A1 (en) 2004-06-15
RU2323744C2 (ru) 2008-05-10
US20060135451A1 (en) 2006-06-22
RU2005113692A (ru) 2006-01-27
CA2504715A1 (en) 2004-06-03
RU2363492C2 (ru) 2009-08-10
JP2006524181A (ja) 2006-10-26
EP1560845A1 (en) 2005-08-10

Similar Documents

Publication Publication Date Title
CN1229501C (zh) Hiv多包膜蛋白疫苗的重组痘苗载体混合物
CN1178956C (zh) 基于癌抑制基因wt1的产物的癌抗原
CN1738833A (zh) Hcv疫苗
CN1606624A (zh) 疫苗
CN1318105A (zh) 负调节Osteoprotegerin配体活性的方法
CN1067382A (zh) 人类乳头状瘤病毒肽的表达以及在致免疫组合物中的应用
CN1549730A (zh) 黄病毒和瘟病毒衣壳蛋白的组成和使用方法
CN1171814A (zh) 多核苷酸结核病疫苗
CA2257137A1 (en) Synthetic hepatitis c genes
CN1526072A (zh) 埃-巴二氏病毒(ebv)肿瘤相关潜伏膜蛋白的胞外结构域的鉴定方法和与之反应的抗体试剂的选择方法
CN1281748C (zh) 为改善IL－12活性而突变的IL－12p40亚基基因及其作为DNA疫苗佐剂的用途
CN1452634A (zh) Hla结合肽及其用途
CN1874787A (zh) 预防/治疗hbv感染和hbv介导疾病的组合物
CN87106696A (zh) 蛋白质及其制备方法，adn的顺序，抗体及其用途，痘病病毒，被转化或感染的细胞用于预防血吸虫病的药剂组合物，以及作为谷胱甘肽-s-转移酶活性的显示剂的用途
CN1657102A (zh) 基于表位的SARS－Cov基因疫苗及其构建
CN101039955A (zh) 与sars冠状病毒刺突蛋白相关的核酸、多肽、表达方法和免疫原性组合物
Isaguliants et al. Immunization with hepatitis C virus core gene triggers potent T-cell response, but affects CD4+ T-cells
CN1727362A (zh) 癌胚抗原阳性肿瘤治疗性疫苗的制备及应用
CN1566342A (zh) Sars冠状病毒的s蛋白的抗原表位、其抗体、编码核酸以及含有它们的组合物
CN1636013A (zh) 可编码hiv辅助蛋白的dna疫苗
CN1555415A (zh) 合成的hcv包膜蛋白和它们用于接种的应用
CN115975053A (zh) 靶向新型冠状病毒的疫苗
CN1289146C (zh) 一种新型预防和治疗乙肝病毒感染的核酸疫苗及制备方法
CN1462636A (zh) 预防和治疗人丙型肝炎病毒感染的重组蛋白疫苗及其用途
CN1249240C (zh) 表达载体pBVTB及其构建方法和在HCV疫苗研究中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication